Inhibition of E2F1 activity and cell cycle progression by arsenic via retinoblastoma protein

• Published in: Cell Cycle Vol. 16; no. 21; pp. 2058 - 2072
• Main Author: Sheldon, Lynn A.
• Format: Report
• Language: English
• Published: Taylor & Francis 02.11.2017
• Subjects: arsenic; cancer therapeutic; Cdc25a; CDK2; cell cycle; cyclins; E2F1; estrogen; phosphorylation; retinoblastoma; transcription
• ISSN: 1538-4101; 1551-4005
• DOI: 10.1080/15384101.2017.1338221

The regulation of cell cycle progression by steroid hormones and growth factors is important for maintaining normal cellular processes including development and cell proliferation. Deregulated progression through the G1/S and G2/M cell cycle transitions can lead to uncontrolled cell proliferation and cancer. The transcription factor E2F1, a key cell cycle regulator, targets genes encoding proteins that regulate cell cycle progression through the G1/S transition as well as proteins important in DNA repair and apoptosis. E2F1 expression and activity is inhibited by inorganic arsenic (iAs) that has a dual role as a cancer therapeutic and as a toxin that leads to diseases including cancer. An understanding of what underlies this dichotomy will contribute to understanding how to use iAs as a more effective therapeutic and also how to treat cancers that iAs promotes. Here, we show that quiescent breast adenocarcinoma MCF-7 cells treated with 17-β estradiol (E2) progress through the cell cycle, but few cells treated with E2 + iAs progress from G1 into S-phase due to a block in cell cycle progression. Our data support a model in which iAs inhibits the dissociation of E2F1 from the tumor suppressor, retinoblastoma protein (pRB) due to changes in pRB phosphorylation which leads to decreased E2F1 transcriptional activity. These findings present an explanation for how iAs can disrupt cell cycle progression through E2F1-pRB and has implications for how iAs acts as a cancer therapeutic as well as how it may promote tumorigenesis through decreased DNA repair.